Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03489239 · ClinicalTrials.gov registry record · Phase 3
Entecavir to TAF Switch
A Phase 3 study of Hepatitis B, sponsored by Thomas Jefferson University.
- Active
- Registry status
- Phase 3
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT03489239: Active Phase 3 study of Hepatitis B, sponsored by Thomas Jefferson University.
NCT03489239 is a Phase 3 study of Hepatitis B that is active but no longer recruiting, run by Thomas Jefferson University. The registered enrollment target is 27 participants, below the 1,628-participant average among 32 other Hepatitis B trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03489239, a Phase 3 study of Hepatitis B, is active but no longer recruiting, sponsored by Thomas Jefferson University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
A research study to observe the safety, efficacy and tolerability of switching from Entecavir (ETV) to Tenofovir Alafenamide TAF in patients with chronic hepatitis B
Primary Outcome
The proportion of subjects with plasma HBV DNA levels below 20 IU/mL at week 48.
Conditions Studied
Interventions
- DRUG Tenofovir Alafenamide
Study Locations (1)
Pennsylvania
- Thomas Jefferson University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2017-11-16 |
| Est. Completion | 2020-09-16 |
| Phase | Phase 3 |
What the registry record for NCT03489239 still lists
NCT03489239 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 1,628-participant average among 32 other Hepatitis B trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Hepatitis B appearing as the primary indexed condition, and to 1 intervention - of which Tenofovir Alafenamide is the first listed.
NCT03489239 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03489239 about?
NCT03489239 is a clinical study titled "Entecavir to TAF Switch". A research study to observe the safety, efficacy and tolerability of switching from Entecavir (ETV) to Tenofovir Alafenamide TAF in patients with chronic hepatitis B
What is the current status of trial NCT03489239?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 27 participants. The study started on 2017-11-16. Estimated completion is 2020-09-16.
What conditions does trial NCT03489239 study?
This clinical trial studies the following conditions: Hepatitis B.
What interventions are being tested in trial NCT03489239?
The interventions under investigation include: Tenofovir Alafenamide (DRUG).
Who is sponsoring clinical trial NCT03489239?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03489239 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis B
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03489239's enrollment target sits among peer trials
27 27th of 32 higher than 6 of 32 other Hepatitis B trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatitis B trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B
COMPLETED · Phase 3
-
Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection
COMPLETED · Phase 3
-
Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation
COMPLETED · Phase 3
-
Evaluation of Patients With Liver Disease
RECRUITING
-
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
RECRUITING · Phase 4
-
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI